Prevalence of immunocompromised patients with a diagnosis of cytomegalovirus infection

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Descriptive study

Study drug and medical condition

• Medical condition to be studied:
  Cytomegalovirus mononucleosis

  Cytomegalovirus infection

Population studied

• Short description of the study population:
  The study population included patients with cytomegaloviral infections aged ≥ 1 year visiting general practices in France and Germany between 2016 and 2020, identified from the IQVIA™ Disease Analyser database.
• Age groups:
  • Paediatric Population (< 18 years)

    • Infants and toddlers (28 days – 23 months)
    • Children (2 to < 12 years)
    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)

      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)

      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)
• Special population of interest:
  Immunocompromised

  Other
• Special population of interest, other:
  Patients with cytomegaloviral infections
• Estimated number of subjects:
  350

Study design details

• Main study objective:
  The primary objectives were to estimate the prevalence of immunocompromised patients, and immunocompromised patients who were diagnosed with CMV.
• Data analysis plan:
  Prevalence of immunocompromised patients: the numerator consisted of immunocompromised patients during the yearly time period. Patients with an underlying condition at any time prior or with a prescription of immunosuppressive therapy 90 days prior the assessment period were included, the denominator consisted of patients that were observable for at least one day during the respective year. Prevalence of immunocompromised patients with CMV: the numerator consisted of immunocompromised diagnosed with CMV during the yearly time period. Patients with an underlying condition any time prior the CVM diagnoses or with a prescription for immunosuppressive therapy 90 days prior the CMV diagnoses date were included, the denominator consisted of patients that were observable for at least one day during the respective year. In both cases the observability for a patient started on the date of the first visit to the practice and ended on the date of the last visit to the practice.